Compare HGV & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HGV | TVTX |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.8B |
| IPO Year | 2017 | 2013 |
| Metric | HGV | TVTX |
|---|---|---|
| Price | $45.35 | $41.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $52.13 | $40.62 |
| AVG Volume (30 Days) | 747.5K | ★ 2.1M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.78 | 92.89 |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $5,047,000,000.00 | N/A |
| Revenue This Year | $25.30 | $44.76 |
| Revenue Next Year | $1.98 | $35.51 |
| P/E Ratio | $59.23 | ★ N/A |
| Revenue Growth | ★ 1.33 | N/A |
| 52 Week Low | $36.79 | $13.88 |
| 52 Week High | $52.08 | $48.61 |
| Indicator | HGV | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 53.40 |
| Support Level | $42.20 | $41.55 |
| Resistance Level | $46.26 | $42.06 |
| Average True Range (ATR) | 1.77 | 2.34 |
| MACD | -0.25 | -0.57 |
| Stochastic Oscillator | 28.29 | 15.42 |
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts and timeshare plans under the Hilton Grand Vacations brand. The company operates in two segments: Real estate sales and financing, and Resort operations and club management. The Real estate sales and financing segment generates revenue from VOI sales and consumer financing, including interest income from loans to members. The Resort operations and club management segment generates revenue from resort management services, club membership fees, and rental of available inventory. The majority of the company's revenue is earned through the Real estate sales and financing segment.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.